News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News SCAI-Led Position Statement on CLTI Spotlights Multispeciality Involvement L.A. McKeown April 27, 2022
News Daily News Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol Michael O'Riordan March 15, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Daily News Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT Michael O'Riordan October 04, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Daily News OMT Boosts Survival in Revascularized Patients at 10 Years Michael O'Riordan June 29, 2021
News Daily News LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD Michael O'Riordan June 18, 2021
News Conference News EAS 2021 Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI Michael O'Riordan June 07, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020